ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Core Insights - The inclusion of neffy on Express Scripts' commercial formularies enhances access to life-saving allergy treatment for patients managing Type 1 allergic reactions, including anaphylaxis [1][3] - neffy is the first FDA-approved epinephrine nasal spray, providing a needle-free alternative to traditional injectables, and is designed for rapid administration [2][5] - ARS Pharmaceuticals anticipates that other payers will follow Express Scripts in providing access to neffy, further expanding its market reach [3] Product Information - neffy 2 mg is indicated for emergency treatment of Type I allergic reactions in patients weighing 30 kg or greater, including both adults and children [2][5] - The product features a shelf-life of 30 months and can withstand temperatures up to 122 degrees Fahrenheit, making it portable and user-friendly [2] - neffy addresses limitations associated with epinephrine autoinjectors, such as fear of needles and complexity, which can lead to delays in treatment during emergencies [15] Market Context - Approximately 40 million people in the U.S. experience Type I allergic reactions, with around 20 million diagnosed and treated for severe reactions in the last three years [15] - Despite the high number of patients, only 3.2 million filled their active epinephrine autoinjector prescriptions in 2023, indicating a significant market opportunity for neffy [15] - The quick turnaround from product introduction to inclusion in formularies (nine weeks) demonstrates the demand and potential for neffy in the market [3]